Advertisement

Predictive Biosciences Company Profile

06:35 EDT 21st May 2013 | BioPortfolio

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. Predictive Biosciences’ commercial division, OncoDiagnostic Laboratory (ODL), is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists and other subspecialty physicians. For additional information, please visit www.predictivebiosci.com.


News Articles [ 768 Associated News Articles listed on BioPortfolio]

Predictive Biosciences names Pierre Cassigneul as new CEO

Molecular diagnostic cancer assays developer Predictive Biosciences has named Pierre Cassigneul as the company's new chief executive officer (CEO).

Predictive Bio allows Arup to offer its bladder cancer assay

Arup Laboratories agreed to offer Predictive Biosciences' CertNDx Bladder Cancer Assay to its clients, including health care  -More- 

Epigenomics, Predictive Biosciences sales and marketing update

MDxHealth, Predictive Biosciences sales and marketing update

Predictive Biosciences to Incorporate Next-Generation Sequencing into CertNDx™ Products

Predictive Biosciences today announced the introduction of next-generation sequencing (NGS) into the company’s CertNDx™ bladder cancer tests. The company has d...

Predictive Biosciences Announces Publication of Recurrence Monitoring Clinical Study

Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced the publication of the Company’s clinical study for the CertNDx™ Bladder Cancer...

Predictive Biosciences führt Prostatakrebstest basierend auf Epigenomics DNA-Methylierungsmarker ein

Das deutsch-amerikanische Krebsdiagnostik-Unternehmen Epigenomics AG (Frankfurt Prime Standard:...

Predictive Biosciences to Present at AACR Annual Meeting and Oak Ridge Conference

Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced the company will present data at two key scientific conferences this month on...

Drugs and Medications [ 13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

Clinical Trials [ 286 Associated Clinical Trials listed on BioPortfolio]

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2

This project aims to validate a predictive model of diabetic retinopathy progression to clinically significant macular edema (CSME) needing photocoagulation and/or vision loss. The Coimbra...

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

The aim of the study is to assess the negative predictive value of the T amplitude variance as a method for risk stratification for patients with an increased risk for SCD.

Predictive Values of Serotonergic Alterations for Outcome - 2

The purpose of this study is to evaluate the predictive value of serotonergic alterations for outcome.

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).

Companies [ 367 Associated Companies listed on BioPortfolio]

Predictive Biosciences

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory p...

Predictive Biosciences, Inc.

Predictive Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented...

Valent BioSciences Corporation

Headquartered in Libertyville, IL, Valent BioSciences is a subsidiary of Tokyo-based Sumitomo Chemical Company and is the worldwide leader in the development, manufacturing and co...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

DaVinci Biosciences LLC

DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through...

More Information about "Predictive Biosciences" on BioPortfolio

We have published hundreds of Predictive Biosciences news stories on BioPortfolio along with dozens of Predictive Biosciences Clinical Trials and PubMed Articles about Predictive Biosciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Predictive Biosciences Companies in our database. You can also find out about relevant Predictive Biosciences Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement